Study of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy

NCT02527746 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

18

Enrollment

INDUSTRY

Sponsor class

Conditions

Neutropenia
Breast Cancer

Interventions

DRUG: F-627
DRUG: EC regimen

Sponsor

EVIVE Biotechnology

Collaborators

[object Object]